Importance of performance status for treatment outcome in advanced pancreatic cancer

doi:10.3748/wjg.v13.i2.224

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2159)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

341

HTML

1348

Figures (1-2)

253

Tables (1-1)

217

Sum=2159

Jan 14, 2007 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (51)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jan 14, 2007; 13(2): 224-227
Published online Jan 14, 2007. doi: 10.3748/wjg.v13.i2.224

Full Size Figure Download Figure

Figure 2 Randomized phase III trial comparing gemcitabine (Gem) vs gemcitabine plus cisplatin (Cis): Subgroups KPS 70%-80% and KPS 90%-100%; Overall survival (OS) by treatment arm (HR = hazard ratio).

Citation: Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007; 13(2): 224-227
URL: https://www.wjgnet.com/1007-9327/full/v13/i2/224.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i2.224